IGF1 and cancer: Cancer-specific survival was significantly associated with the CA repeat polymorphism (p = 0.013);Patients with at least one C-T haplotype showed significantly worse survival compared with those who had no C-T haplotype (p = 0.0003)The median survival time was 41 months and 61 months for patients with and without the long allele of the IGF-1 polymorphism, respectively (p = 0.019);